Growth Hormone Releasing Peptide-2

This page shows anti-doping rule violation data we have registered for Growth Hormone Releasing Peptide-2.

Number of cases in Growth Hormone Releasing Peptide-2 Last 10 Years

Growth Hormone Releasing Peptide-2

Growth Hormone Releasing Peptide-2 ranks #85 globally among prohibited substances, with 29 registered cases (0.2% of all violations) among all sports tracked by the Anti-Doping Database, which contains 14,828 verified cases. Russia leads with 6 cases, while Cycling is the most affected sport (9 cases).

Cases of Growth Hormone Releasing Peptide-2 by Sport
Cycling
9
Track and field
7
Weightlifting
5
Rugby
2
Boxing
1
Top Sport: Cycling

9

Cycling cases

0%

Of all violations

29

Total Growth Hormone Releasing Peptide-2 cases
Cycling's share of Growth Hormone Releasing Peptide-2 violations 0%
9 of 29

Cycling has the most recorded cases of Growth Hormone Releasing Peptide-2 violations globally, with 9 registered cases — 0% of all 29 verified cases.

Cases of Growth Hormone Releasing Peptide-2 by Country
Russia
6
Italy
4
Poland
3
China
3
Spain
2
Top Country: Russia

6

Russia cases

20.7%

Of all violations

29

Total Growth Hormone Releasing Peptide-2 cases
Russia's share of Growth Hormone Releasing Peptide-2 violations 20.7%
6 of 29

Russia leads significantly in Growth Hormone Releasing Peptide-2 violations globally, with 6 registered cases — 20.7% of all 29 verified cases.

Global Substance Ranking

Growth Hormone Releasing Peptide-2 ranks #85 of 360 prohibited substances in the Anti-Doping Database.

#1 Stanozolol
1,379
#2 Methandienone
843
#3 Norandrosterone
787
#4 Testosterone
772
···
#85 Growth Hormone Releasing Peptide-2
29
About This Ranking

This ranking covers only prohibited substances with verified case records in the Anti-Doping Database. Procedural violations (whereabouts failures, refusals to test, etc.) are excluded.

Active Sanctions — Expiry Year
Gender Distribution
Male 65.5%
19 cases
Female 34.5%
10 cases
Analysis: shows an unusually high proportion of female cases (34.5%) compared to the global average (19.9%), a difference of 14.6 percentage points. Global average: 80.1% male, 19.9% female
Average Suspension Length
42.3
months
Growth Hormone Releasing Peptide-2
30.2
months
Global average

The average suspension for Growth Hormone Releasing Peptide-2 violations is 42.3 months, longer than the global average of 30.2 months.

This substance increases food intake in healthy men according a study. Links: http://www.ncbi.nlm.nih.gov/pubmed/15230633 http://www.drugs.com/international/pralmorelin.html http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2824650/

If you use this data, please credit The Anti-Doping Database

The intelligence tool for anti-doping professionals

Used by journalists, sport lawyers, NADOs and researchers worldwide for proactive strategy — not just post-case research.

 

As a subscriber you get instant access to verified, structured anti-doping case data — from hours of research to seconds:

  • Complete athlete and sanction details
    • Identity, ban periods, substances used, test type, violation information and more.
  • Verified documents and case materials
    • Access sanction decisions, PDFs and official sources when available.
  • Advanced insights and historical trends
    • Statistics across sports, countries, substances and year-by-year comparisons — for proactive planning, not just post-case analysis.

The Anti-Doping Database currently contains 14,828 verified anti-doping rule violations across all sports and all countries, and is updated regularly.